# LianBio (LIAN)

Source: https://www.quantisnow.com/company/LIAN
Generated: 2026-11-14T04:37:14.130Z

- Ticker: LIAN
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2021
- Website: https://www.lianbio.com

## About

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

## Latest LIAN news and filings

- 2024-11-25 00:27 UTC [Leadership Update] [Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors](https://www.quantisnow.com/insight/ascentage-pharma-appoints-ms-marina-s-bozilenko-and-dr-debra-5789242)
- 2024-04-11 20:10 UTC [SEC Form 4] [Gu Ehong sold $7,513 worth of Ordinary Shares (1,731 units at $4.34) and returned $5,724 worth of Ordinary Shares to the company (17,889 units at $0.32), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/gu-ehong-sold-7513-worth-of-ordinary-shares-1731-units-5406109)
- 2024-03-21 12:00 UTC [SEC Form 15-12G filed by LianBio](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-lianbio-5359861)
- 2024-03-15 19:44 UTC [Market Insight] [What's Going On With LianBio (LIAN) Stock?](https://www.quantisnow.com/insight/whats-going-on-with-lianbio-lian-stock-5347934)
- 2024-03-13 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by LianBio](https://www.quantisnow.com/insight/sec-form-effect-filed-by-lianbio-5339636)
- 2024-03-12 12:30 UTC [SEC Form F-6 POS filed by LianBio](https://www.quantisnow.com/insight/sec-form-f-6-pos-filed-by-lianbio-5336411)
- 2024-03-12 12:02 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by LianBio](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-lianbio-5336272)
- 2024-03-12 12:01 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by LianBio](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-lianbio-5336263)
- 2024-03-12 12:00 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by LianBio](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-lianbio-5336261)
- 2024-03-12 11:56 UTC [SEC Form POS AM filed by LianBio](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-lianbio-5336179)
- 2024-03-11 11:51 UTC [SEC Form 25 filed by LianBio](https://www.quantisnow.com/insight/sec-form-25-filed-by-lianbio-5332479)
- 2024-03-01 00:45 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by LianBio (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-lianbio-amendment-5307237)
- 2024-02-28 12:13 UTC [Market Chatter] [LianBio Reports Voluntarily Delisting From Nasdaq;](https://www.quantisnow.com/insight/lianbio-reports-voluntarily-delisting-from-nasdaq-5298826)
- 2024-02-28 12:00 UTC [Dividends] [LianBio Announces Voluntarily Delisting from Nasdaq](https://www.quantisnow.com/insight/lianbio-announces-voluntarily-delisting-from-nasdaq-5298648)
- 2024-02-20 22:27 UTC [SEC Form 4] [Poukalov Konstantin exercised 36,300 units of Ordinary Shares at a strike of $2.52 and covered exercise/tax liability with 19,218 units of Ordinary Shares (SEC Form 4)](https://www.quantisnow.com/insight/poukalov-konstantin-exercised-36300-units-of-ordinary-shares-at-a-5276783)
- 2024-02-20 22:25 UTC [SEC Form 4] [Perceptive Advisors Llc exercised 72,600 units of Ordinary Shares at a strike of $2.52 and covered exercise/tax liability with 38,436 units of Ordinary Shares (SEC Form 4)](https://www.quantisnow.com/insight/perceptive-advisors-llc-exercised-72600-units-of-ordinary-shares-at-5276769)
- 2024-02-20 22:23 UTC [SEC Form 4] [Stone Adam Leo exercised 36,300 units of Ordinary Shares at a strike of $2.52 and covered exercise/tax liability with 19,218 units of Ordinary Shares (SEC Form 4)](https://www.quantisnow.com/insight/stone-adam-leo-exercised-36300-units-of-ordinary-shares-at-5276758)
- 2024-02-20 21:11 UTC [SEC Form 4] [Gianakakos Anastasios exercised 36,300 units of Ordinary Shares at a strike of $2.52 and covered exercise/tax liability with 19,218 units of Ordinary Shares, increasing direct ownership by 47% to 53,630 units (SEC Form 4)](https://www.quantisnow.com/insight/gianakakos-anastasios-exercised-36300-units-of-ordinary-shares-at-a-5275289)
- 2024-02-20 21:10 UTC [SEC Form 4] [Silbermann Susan Michele exercised 36,300 units of Ordinary Shares at a strike of $2.52 and covered exercise/tax liability with 19,218 units of Ordinary Shares (SEC Form 4)](https://www.quantisnow.com/insight/silbermann-susan-michele-exercised-36300-units-of-ordinary-shares-at-5275266)
- 2024-02-13 18:13 UTC [Market Insight] [Why IPG Photonics Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session](https://www.quantisnow.com/insight/why-ipg-photonics-shares-are-trading-lower-by-around-11-5253819)
- 2024-02-13 16:43 UTC [Market Chatter] [LianBio shares are trading higher after the company completed its strategic review and determined to initiate the wind down of its operations, including the sale of remaining pipeline assets, delisting of ADS and workforce reductions. Also, the company declared a $4.80 special dividend.](https://www.quantisnow.com/insight/lianbio-shares-are-trading-higher-after-the-company-completed-its-5253533)
- 2024-02-13 15:09 UTC [Market Insight] [Ecolab Posts Strong Results, Joins Masonite International, Impinj And Other Big Stocks Moving Higher On Tuesday](https://www.quantisnow.com/insight/ecolab-posts-strong-results-joins-masonite-international-impinj-and-other-5253164)
- 2024-02-13 12:09 UTC [Market Chatter] [LianBio Completes Strategic Review And Determined To Initiate The Wind Down Of Its Operations, Including Sale Of Remaining Pipeline Assets, Delisting Of ADSs And Workforce Reductions; Board Has Declared Special Dividend Of $4.80/Sharea](https://www.quantisnow.com/insight/lianbio-completes-strategic-review-and-determined-to-initiate-the-wind-5252323)
- 2024-02-13 12:04 UTC [SEC Form 8-K] [LianBio filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/lianbio-filed-sec-form-8-k-costs-associated-with-exit-or-5252298)
- 2024-02-13 12:00 UTC [Dividends] [LianBio Announces Completion of Strategic Review](https://www.quantisnow.com/insight/lianbio-announces-completion-of-strategic-review-5252222)
- 2024-01-03 17:00 UTC [Market Insight] [B of A Securities Downgrades LianBio: Here's What You Need To Know](https://www.quantisnow.com/insight/b-of-a-securities-downgrades-lianbio-heres-what-you-need-5163879)
- 2024-01-03 14:09 UTC [Market Chatter] [B of A Securities Downgrades LianBio to Underperform, Lowers Price Target to $3](https://www.quantisnow.com/insight/b-of-a-securities-downgrades-lianbio-to-underperform-lowers-price-5163426)
- 2024-01-03 12:58 UTC [Analyst Downgrade] [LianBio downgraded by BofA Securities with a new price target](https://www.quantisnow.com/insight/lianbio-downgraded-by-bofa-securities-with-a-new-price-target-5162973)
- 2023-12-26 21:16 UTC [Market Chatter] [Pursuant To The APA, LianBio Development Will Receive A Payment Of $25M; Eligible To Receive A Sales Milestone Payment Of $5M Within 60 Days After The End Of The First Calendar Year If Net Sales Of The Licensed Products In China Exceed $20M](https://www.quantisnow.com/insight/pursuant-to-the-apa-lianbio-development-will-receive-a-payment-5154978)
- 2023-12-26 21:13 UTC [Market Chatter] [On Dec 22, LianBio Development Limited, Janssen Pharmaceutica Nv, LianBio Entered Into An Asset Purchase Agreement; LianBio Development, Certain Affiliates Will Sell To Janssen All Of Seller Entities' Rights, Tile Interests In Products Licensed To Unit](https://www.quantisnow.com/insight/on-dec-22-lianbio-development-limited-janssen-pharmaceutica-nv-lianbio-5154961)
- 2023-12-26 21:10 UTC [SEC Form 3] [New insider Gu Ehong claimed ownership of 78,493 units of Ordinary Shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-gu-ehong-claimed-ownership-of-78493-units-of-5154954)
- 2023-12-26 21:07 UTC [SEC Form 8-K] [LianBio filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement](https://www.quantisnow.com/insight/lianbio-filed-sec-form-8-k-entry-into-a-material-definitive-5154931)
- 2023-12-26 07:16 UTC [Market Chatter] [LianBio Enters Into Agreement With Janssen Pharmaceutical, Assigns NBTXR3 Rights In China And Other Asian Markets For $25M](https://www.quantisnow.com/insight/lianbio-enters-into-agreement-with-janssen-pharmaceutical-assigns-nbtxr3-rights-5154163)
- 2023-12-22 12:26 UTC [Analyst Downgrade] [LianBio downgraded by Jefferies with a new price target](https://www.quantisnow.com/insight/lianbio-downgraded-by-jefferies-with-a-new-price-target-5152281)
- 2023-12-22 10:32 UTC [Market Chatter] [Jefferies Downgrades LianBio to Hold, Lowers Price Target to $4](https://www.quantisnow.com/insight/jefferies-downgrades-lianbio-to-hold-lowers-price-target-to-4-5152070)
- 2023-12-20 13:12 UTC [Market Chatter] [LianBio Announces Departure Of Chief Financial Officer Yi Larson, Effective December 19, 2023; Board Of Directors Has Appointed Ehong (Maggie) Gu, Current VP, Head Of Global Finance, As Interim Chief Financial Officer](https://www.quantisnow.com/insight/lianbio-announces-departure-of-chief-financial-officer-yi-larson-effective-5148074)
- 2023-12-20 13:05 UTC [SEC Form 8-K] [LianBio filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/lianbio-filed-sec-form-8-k-leadership-update-regulation-fd-disclosure-5148047)
- 2023-12-20 13:00 UTC [LianBio Announces Departure of Chief Financial Officer](https://www.quantisnow.com/insight/lianbio-announces-departure-of-chief-financial-officer-5147972)
- 2023-12-19 21:26 UTC [SEC Form 8-K] [LianBio filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/lianbio-filed-sec-form-8-k-leadership-update-regulation-fd-disclosure-5146611)
- 2023-12-19 21:13 UTC [Market Chatter] [LianBio Says CEO Yizhe Wang Has Resigned To Pursue Other Opportunities; Adam Stone Named As Interim CEO](https://www.quantisnow.com/insight/lianbio-says-ceo-yizhe-wang-has-resigned-to-pursue-other-5146426)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/LIAN
- Earnings history: https://www.quantisnow.com/earnings/LIAN
- Dividend history: https://www.quantisnow.com/dividends/LIAN
- Insider transactions: https://www.quantisnow.com/insiders/LIAN
- Options chain: https://www.quantisnow.com/options/LIAN
- SEC 8-K filings only: https://www.quantisnow.com/company/LIAN/8-k
- RSS and alerts for LIAN: https://www.quantisnow.com/docs/rss-feeds.md